Drug guidance
Sacubitril/valsartan for treating chronic heart failure with reduced ejection fraction
Condition
Cardiovascular
4 January 2022
Published on 02 May 2019
Last Updated on 04 Jan 2022
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
Sacubitril/valsartan 50 mg, 100 mg and 200 mg tablets to reduce the risk of cardiovascular death and hospitalisation for heart failure in patients:
with chronic heart failure classified by New York Heart Association (NYHA) Class II - IV symptoms; and
with left ventricular ejection fraction of 40% or less; and
who are receiving concomitant optimal standard chronic heart failure treatment, which includes a beta-blocker, unless contraindicated or not tolerated; and
who remain symptomatic despite already receiving a stable dose of an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), unless such treatment is contraindicated or cannot be tolerated.
Sacubitril/valsartan must not be co-administered with an ACE inhibitor or an ARB.
Subsidy status
Sacubitril/valsartan 50 mg, 100 mg and 200 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.